Fixed combination niacin/laropiprant - revival of the use of a class of lipid-modifying drugs

Abstract

Niacin (nicotinic acid) reduces aterogennic particles and increases protective HDL-cholesterol. The combination with laropiprant reduces side effects, especially flushing.

Keywords

• niacin
• nicotinic acid
• laropiprant
• lipid
• modifying drugs